Please login to the form below

Not currently logged in


This page shows the latest osteoporosis news and features for those working in and with pharma, biotech and healthcare.

Amgen and UCB’s Evenity finally approved, but with label warnings

Amgen and UCB’s Evenity finally approved, but with label warnings

Amgen’s R&D head David Reese welcomed the FDA approval, and said postmenopausal osteoporosis was a significant women's health issue that “far too often” gets overlooked. ... One in two women will experience a fracture due to osteoporosis in her

Latest news

More from news
Approximately 10 fully matching, plus 187 partially matching documents found.

Latest Intelligence

  • Deal Watch September 2016 Deal Watch September 2016

    Dr Reddy's has expanded its collaboration with Amgen in India adding three approved products: Xgeva for treating bone metastases, Vectibix in colorectal cancer therapy and Prolia for osteoporosis.

  • Medical affairs - the time for change is now Medical affairs - the time for change is now

    FLIP aims at supporting the implementation of Fracture Liaison Services (FLS) for secondary fracture prevention in patients suffering from osteoporosis. ... FLS is a coordinated multidisciplinary approach to patient care. To date the FLIP programme has

  • Pharma deals in June 2015 Pharma deals in June 2015

    The device, which has been tested in the clinic for the delivery of parathyroid hormone in osteoporosis patients, can be programmed to release drug at precise times and on a

  • Pharma deals during December 2014 Pharma deals during December 2014

    34 (PTH) delivered using Zosano's microneedle patch system for the treatment of osteoporosis.

  • Investing in the future of R&D Investing in the future of R&D

    One of UCB's brightest prospects is its osteoporosis candidate romosozumab. In January phase II trial results were published that showed significant increases in low bone mineral density at both spine ... and hip and in June the monoclonal antibody began

More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Cuttsy+Cuttsy launch their latest patient e-book

    Osteoporosis is a chronic condition that affects up to one in three people aged 50 and over. ... If you or someone you know has osteoporosis, this book might help take some of the unknown away.

  • How can pharma engage with key stakeholders on NHS service transformation?

    NHS RightCare provides examples of this with its long-term condition scenarios, such as ‘Susan’s Story: Osteoporosis’, where costs are shown to be reduced by a factor of 10 if

  • Atlantis Healthcare

    haemophilia. hepatitis C. incontinence. multiple sclerosis. osteoporosis . rheumatoid arthritis. Additionally, Atlantis has delivered many programmes to support rare diseases, health screening and blood donor management.

  • Maximising ROI from mature brands

    News that Eli Lilly and Co has forecast a drop in 2014 profits and reduced its sales outlook because of generic competition to its Cymbalta antidepressant and Evista drug for osteoporosis,

  • Cuttsy + Cuttsy

    On the eve of ‘World Osteoporosis Day’ (, Cuttsy Cuttsy are proud to launch their latest e-book ‘Osteoporosis…in plain English’.

More from PMHub
Approximately 1 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...